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Assessment of an In Silico Mechanistic Model 
for Proarrhythmia Risk Prediction Under the 
CiPA Initiative
Zhihua Li1, Bradley J. Ridder1, Xiaomei Han1, Wendy W. Wu1, Jiansong Sheng1, Phu N. Tran1, Min Wu1, 
Aaron Randolph1, Ross H. Johnstone2, Gary R. Mirams3, Yuri Kuryshev4, James Kramer4, Caiyun Wu4, 
William J. Crumb Jr.5 and David G. Strauss1
The international Council on harmonization (iCh) s7B and e14 regulatory guidelines are sensitive but not specific for 
predicting which drugs are pro- arrhythmic. in response, the Comprehensive In Vitro Proarrhythmia assay (CiPa) was 
proposed that integrates multi- ion channel pharmacology data in vitro into a human cardiomyocyte model in silico 
for proarrhythmia risk assessment. Previously, we reported the model optimization and proarrhythmia metric 
selection based on CiPa training drugs. in this study, we report the application of the prespecified model and metric 
to independent CiPa validation drugs. over two validation datasets, the CiPa model performance meets all pre- 
specified measures for ranking and classifying validation drugs, and outperforms alternatives, despite some in vitro 
data differences between the two datasets due to different experimental conditions and quality control procedures. 
This suggests that the current CiPa model/metric may be fit for regulatory use, and standardization of experimental 
protocols and quality control criteria could increase the model prediction accuracy even further.
In the 1990s to early 2000s, it was recognized that drug- induced 
Torsade de Pointes (TdP), a rare but potentially fatal arrhythmia,1 
is associated with pharmacological block of a potassium channel 
encoded by the human ether- à- go- go related gene (hERG) and 
electrocardiographic QTc prolongation.2 This finding led to the 
establishment of two International Council on Harmonization 
(ICH) regulatory guidelines (S7B and E14) for cardiac safety 
assessment that focus on assessing the potential of a drug to 
cause hERG block and QT prolongation.2 Although sensitive 
for identifying drugs that can cause TdP, these biomarkers have 
low specificity.3 This has caused the unintended effect of depri-
oritizing or excluding many drugs from development that may 
not have actual TdP risk.4 In response, a new paradigm—the 
Comprehensive In Vitro Proarrhythmia Assay (CiPA)—was 
 proposed that takes into account drug effects on multiple cardiac 
ion channels in vitro and integrates these effects into a mechanis-
tic in silico cardiomyocyte model to predict TdP risk as the direct 
end point.2–4
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 The current cardiac safety paradigm is outlined in ICH S7B 
and E14 guidelines, which focuses on surrogate end points 
(human ether- à- go- go related gene (hERG) block and QT pro-
longation), and is highly sensitive but not very specific for pre-
dicting pro- arrhythmic (TdP) risk.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Can mechanistic in silico models show high TdP risk predic-
tion accuracy in a rigorous prospective study specified by the 
newly proposed CiPA paradigm?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 The CiPA in silico model and the qNet/torsade metric score 
metric demonstrate high accuracy in TdP risk prediction, which 
suggests it may be fit for regulatory use under the CiPA 
paradigm.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 The established in silico model, together with other compo-
nents of CiPA, might greatly increase the accuracy of regulatory 
assessment of TdP risk for clinical therapeutics.
Study Highlights
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Although numerous studies have presented in silico models for 
TdP risk prediction before,2,5–13 the intended implementation of 
CiPA as a regulatory paradigm calls for a more stringent model 
qualification process. Thus, a rigorous approach was designed by 
the CiPA Steering Committee to strictly separate model training 
from validation in a stepwise manner (Figure 1). As a first step, 28 
compounds were selected and categorized into high, intermediate, 
and low/no risk of TdP, and then subdivided into a training set 
of 12 and a validation set of 16 compounds, by a team of clinical 
cardiologists and electrophysiologists based on publicly available 
data and expert opinion.3 A consensus base model, the O’Hara- 
Rudy dynamic (ORd) cardiac cell model,14 was selected by a panel 
of cardiac modeling experts, which then went through model opti-
mization and metric development based on in vitro channel block 
data for the 12 training drugs.3 The resulting model and metric 
were then “frozen” and applied to the 16 validation drugs for inde-
pendent validation, with the prediction outcome evaluated by pre-
defined performance measures. This prospective design could be 
more stringent than the cross- validation approach commonly used 
in the literature,5–7 and serves as a general framework for model 
qualification under the CiPA paradigm.
Previously, we have reported the optimization of the base ORd 
model into CiPAORdv1.0,15–18 the selection of the net charge 
metric “qNet” for TdP risk prediction,15 and the development of 
an uncertainty quantification method to translate experimental 
variability into probability distributions for the risk metric for the 
12 CiPA training drugs.17 In this study, we report the use of this 
predefined modeling framework for predicting the TdP risk levels 
of the 16 validation drugs, to finish the model qualification process 
defined in Figure 1 and evaluate the prediction performance.
RESULTS
Predefining the model, metric, and performance measures 
prior to validation
In our previous work using manual patch clamp training data, 
we reported that the prediction error using the pro- arrhythmic 
metric qNet was lowest at 1–4 × maximum free therapeu-
tic concentration (Cmax), where experimental data were most 
complete.17 We also concluded that three cardiac currents have 
the most significant impact on TdP risk prediction using qNet 
in CiPAORdv1.017: IKr (rapidly activating delayed rectifier po-
tassium current), INaL (late sodium current), and ICaL (L- type 
calcium current). In addition, the block of INa (peak sodium 
current) is important for metric calculation due to its potential 
to cause depolarization failure.17 Based on these training results, 
we define the mean qNet value averaged across 1–4 × Cmax as the 
torsade metric score for each drug, computed by CiPAORdv1.0 
with drug effects on the four essential currents (IKr, INa, 
INaL, and ICaL) as model inputs. The drug effects on IKr/
hERG were characterized by five dynamic parameters captured 
by a hERG dynamic protocol,16,19 whereas effects on the other 
three currents were characterized by concentration of half in-
hibition (IC50) and Hill coefficients captured by block potency 
experiments.20 This set of model inputs17 was all from manual 
patch clamp systems at physiological temperature. The distribu-
tion of torsade metric scores for the 12 drugs using this manual 
Figure 1 The Comprehensive In Vitro Proarrhythmia Assay (CiPA) in silico model qualification procedure. Shown is the flowchart of the CiPA 
in silico model qualification process designed by the CiPA Steering Committee. The model training process includes model optimization and 
metric development using published human cardiomyocyte experimental data originally used for O’Hara Rudy (ORd) model development, and 
newly acquired in vitro drug block data against various cardiac currents for the 12 training compounds. This training process was performed 
prior to, and strictly separated from, the model validation process—where the model and metric predefined by the training data were used to 
predict the TdP risk of the 16 validation drugs using their in vitro data. The model performance measures (Validation Strategy/Supplementary 
Text S1) to evaluate the prediction accuracy were also prespecified before the validation began.
CiPA training drugs (12)Base cardiomyocyte model
Model optimization
Metric development
Freeze the model and metric
Define performance measures
CiPA validation drugs (16)
Compare prediction accuracy to pre-
defined performance measures 
Predict validation drugs
Model training
Model validation
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training dataset can be found in Figure 2a. The two thresholds 
that classify drugs into three TdP risk categories were also calcu-
lated and “frozen” based on the training data: Threshold 1 (sep-
arating low from intermediate/high risk) has a value of 0.0689 
and threshold 2 (separating high from intermediate/low risk) 
has a value of 0.0579 μC/μF.
In addition, within a large- scale multisite study that is ongoing 
to collect in vitro data for CiPA drugs using various automated 
high throughput patch clamp systems (HTS), one participating 
site (site 6) finished the block potency experiments for the 12 
training drugs. As a first step to test the possibility of using auto-
mated HTS data for TdP risk assessment under the CiPA initia-
tive, we combined site 6 HTS block potency data (IC50 and Hill 
coefficients) for INaL, INa, and ICaL with manual dynamic data 
for IKr/hERG to form a “hybrid” training dataset. The difference 
between the manual and hybrid datasets in terms of experimental 
conditions, and the corresponding training drug block data can be 
found in the validation report (Tables 1 and 2 of Supplementary 
Text S2). The torsade metric score distribution for the hybrid train-
ing dataset is shown in Figure 2b, with the two thresholds calcu-
lated as 0.0671 and 0.0581 μC/μF, respectively.
Prior to the initiation of model validation, a comprehen-
sive set of model performance measures (Table 1 of Validation 
Strategy/Supplementary Text S1) were agreed upon by the CiPA 
Steering Committee as well as expert electrophysiologists from 
the CiPA Ion Channel Working Group. The rationale of selecting 
these performance measures and associated acceptable levels are 
elaborated in the validation strategy.
Figure 2 The distribution of torsade metric scores for the 12 Comprehensive In Vitro Proarrhythmia Assay training drugs. For each of the 
training drugs, 2,000 torsade metric scores were calculated using the uncertainty quantification method developed previously.17 The 95% 
confidence interval and median point of the 2,000 torsade metric scores for each drug are shown as horizontal error bars in this figure. 
Threshold 1 and threshold 2 are calculated by ordinal logistic regression (see Supplementary Text S2) to separate the three TdP risk 
categories (red: high risk; blue: intermediate risk; green: low/no risk). The values of these thresholds are given in the main text. Drugs are 
sorted by the median values of their torsade metric scores in each dataset. Results shown are for the manual (a) and hybrid (b) training 
datasets, respectively.
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Application of the predefined modeling framework to 
validation drugs
Next, we applied the modeling framework defined above to the 
16 validation drugs. For the IKr/hERG current, the CiPA hERG 
dynamic protocol16 was used to obtain dynamic drug- hERG 
interaction parameters at physiological temperature. For non- 
hERG currents (INaL, INa, and ICaL), drug block potency data 
were collected either through the manual patch clamp system at 
physiological temperature, or the site 6 automated HTS system 
at ambient temperature, both exactly matching the experimen-
tal conditions for the manual or hybrid training datasets, respec-
tively. In this way, two semi- independent validation datasets (one 
manual and one hybrid) were generated with shared IKr/hERG 
 dynamic data and different non- hERG block potency data, which 
were used to calculate qNet and the torsade metric scores for each 
validation drug. All the drug block parameters, as well as Cmax 
used for metric calculation, can be found in the validation report 
(Tables 3–5 of Supplementary Text S2).
Predefined performance measures
There are two types of performance measures for CiPA- like risk 
prediction models: those evaluating the model’s ability to rank 
order the risk levels of drugs without a specific threshold, and 
those using specific thresholds to classify drugs into distinct risk 
categories.21 Accordingly, the validation strategy (Supplementary 
Text S1) prespecifies two types of outcome measures for CiPA 
model performance evaluation: ranking performance measures 
and classification performance measures.
Ranking performance measures
For the first ranking performance measure, we used all possible 
cutoff points along the continuous torsade metric scores to make 
binary predictions for validation drugs and assemble the results 
into two kinds of receiver operating characteristic (ROC) curves 
(high- or- intermediate vs. low for ROC1, and high vs. low- or- 
intermediate risk for ROC2). The area under the curve (AUC) 
of each ROC curve indicates the probability of correctly ranking 
a higher risk drug above a lower risk one.22 For both ROC1 and 
ROC2, we repeated the analysis 10,000 times by independent 
sampling (with replacement) from the probability distributions 
of torsade metric scores of the validation drugs. The representa-
tive ROC curves as well as distribution of AUCs across 10,000 
ROC1 curves are shown for the manual (Figure 3a) and hy-
brid (Figure 3b) validation dataset, respectively. The results 
suggest that the probability of ranking a high- or- intermediate- 
risk drug above (torsade metric score lower than) a low- risk 
drug using CiPAORdv1.0 is 0.89 (95% confidence interval 
(CI) = 0.84–0.95) and 0.98 (0.93–1) for manual and hybrid 
Figure 3 The receiver operating characteristic (ROC)1 analysis to estimate the probability of ranking high- risk or intermediate- risk drugs 
above low- risk drugs. For ROC1 analysis, high- risk and intermediate- risk drugs are combined into one category (high- or- intermediate), and 
10,000 ROC curves are constructed by sampling the torsade metric score distributions for the manual (a) and hybrid (b) validation datasets, 
respectively. Left panel of a or b: one representative example of the 10,000 ROC curves and the corresponding area under the curve (AUC). 
Insert: the underlying ranking of the 16 drugs (X axis: rank of 1–16; drug names not shown on X axis for figure clarity) for this particular ROC 
curve according to their torsade metric scores (Y axis); L: low/no risk drugs; H- or- I: high- or- intermediate risk drugs. Note that H- or- I drugs 
(black) generally have a torsade metric score lower than L drugs (white), indicating a higher ranking of Torsade de Pointes risk. Right panel of a 
or b: Distribution of the AUCs across the 10,000 ROC curves.
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validation datasets, respectively. Similarly, for ROC2 curves 
(Figure 2 of Validation Report/Supplementary Text S2), 
the probability of ranking a high- risk drug above (torsade 
metric score lower than) an intermediate- risk or low- risk 
drug is 1 (0.92–1) and 0.94 (0.88–0.98) for manual and 
hybrid validation datasets, respectively. The median val-
ues of all these AUCs exceed or are very close to the pre-
defined “excellent” ranking performance level (AUC > ~0.9; 
Table 1 of Supplementary Text S1). The second rank per-
formance measure Pairwise Comparison, which evaluates 
rank performance across all three risk classes without category 
combining (Validation Strategy/Supplementary Text S1), 
also achieves predefined “excellent” performance level 
(>0.9) for both manual and hybrid datasets (Figure 3 of 
Supplementary Text S2).
Likelihood ratio tests to evaluate classification 
performance
Likelihood ratio (LR) tests were prespecified to evaluate the mod-
el’s ability to use predefined thresholds 1 and 2 (Figure 2) for 
TdP risk classification. For each threshold, two LRs can be cal-
culated: LR for positive results (LR+) and LR for negative results 
(LR−).23 The resulting values (Table 7 of Validation Report/ 
Supplementary Text S2) suggest that, using threshold 1 as a cut-
off value, a high- risk or intermediate- risk drug is 4.5 and 8 × 105 
times (median of LR+) more likely to be classified into the high- 
or- intermediate category, but 8.8 and 5.5 times (median of 1/
LR−) less likely to be classified into the low- risk category, com-
pared to a low- risk drug, for the manual and hybrid validation 
datasets, respectively. Similarly, using threshold 2, a high- risk 
drug is 12 and 6 times more likely to be classified into the high 
category, but 9 × 105 and 3.7 times less likely to be classified into 
the low- risk or intermediate- risk category, compared to a low- risk 
or intermediate- risk drug, for the manual and hybrid dataset, re-
spectively. These measures exceed or are very close to the “good” 
classification performance levels predefined by the Validation 
Strategy (LR+ and 1/LR− >~5 for good and >~10 for excellent 
performance).
Mean classification error to estimate classification 
performance
A second classification measure (mean classification error)7 was 
prespecified to estimate the model’s accuracy in classifying drugs 
into all three categories, which can be visualized by comparing the 
torsade metric score distributions for the 16 validation drugs to the 
classification thresholds (Figure 4). Generally, high- risk drugs 
(black) have most of their distributions left of threshold 2, and 
low- risk drugs (white) right of threshold 1, whereas intermediate- 
risk drugs (gray) are in between.
There are some drugs that fall out of this pattern. For example, 
for the manual validation dataset (Figure 4a), the intermediate- risk 
drug risperidone has 75% (0.75 fraction) of its torsade metric score 
distribution classified as low risk (right of threshold 1). However, this 
fraction is lower than most low- risk drugs (Table 8 of Validation 
Report/Supplementary Text), suggesting risperidone is still con-
sidered more dangerous than most low- risk drugs by the model. 
Similarly, for the hybrid dataset (Figure 4b), the intermediate- risk 
drugs clozapine and risperidone have most of their torsade metric 
score distributions right of threshold 1. However, these distributions 
have the lower bounds of the 95% CI entering the intermediate- risk 
zone (between threshold 1 and 2), in contrast to true low- risk drugs, 
whose torsade metric score distributions have the entire 95% CI right 
of threshold 1. This suggests that these classification outliers actually 
arise from the use of discrete thresholds to arbitrarily cut the contin-
uum of risk levels,21 which may be remedied by using ranking instead 
of classification for risk evaluation. Other drugs, such as metoprolol 
in the manual dataset, and disopyramide and domperidone in the 
hybrid dataset, are incorrectly predicted by both ranking and classifi-
cation (outliers). Nonetheless, when summarizing all distributions of 
the 16 validation drugs, the mean classification error is 0.1974 (95% 
CI = 0.1973–0.1975) and 0.2580 (0.2579–0.2581) for the manual 
and hybrid datasets, respectively, both reaching the “excellent” per-
formance level predefined by Validation Strategy (Supplementary 
Text S1).
Some outliers may be associated with in vitro data 
discrepancy
The above finding that the few outliers (those incorrectly pre-
dicted by both ranking and classification) do not overlap between 
the two datasets raised a possibility that they might be caused by 
dataset- specific experimental data bias. Because the two datasets 
share the same IKr/hERG data, we compared the drug block po-
tency data on the other essential currents. Indeed, the low- risk 
drug metoprolol is incorrectly classified as intermediate risk in 
the manual dataset but correctly predicted in the hybrid dataset 
(Figure 4), and this is associated with the fact that there seems 
to be an underestimation of INaL block (to offset hERG block 
and decrease TdP risk24) in the manual dataset but not the hybrid 
dataset (Figure 5a). An opposite prediction pattern was seen for 
the high- risk drug disopyramide (Figure 4), which is also associ-
ated with discrepancy in INaL block between the two datasets 
(Figure 5b). Similarly, the intermediate- risk drug domperidone 
is correctly predicted in the manual dataset but incorrectly pre-
dicted as a high- risk drug in the hybrid dataset (Figure 4), consis-
tent with the fact that there is a strong ICaL block to offset hERG 
block and suppress TdP potential25 in the manual dataset but not 
the hybrid dataset (Figure 5c). Interestingly, these discrepancies 
may reflect a systematic bias between the two datasets, with most 
drugs’ INaL IC50s in the manual dataset being larger than (25 
of 28 drugs) and ICaL IC50s being smaller than (21 of 28 drugs) 
those in the hybrid dataset (Tables 2 and 4 in Supplementary 
Text). Preliminary results from our internal investigation suggest 
the different experimental conditions (e.g., use of veratridine in 
the manual dataset but ATX- II in the hybrid dataset as INaL 
enhancers) and lack of standard quality control criteria may con-
tribute to the in vitro data bias that leads to incorrect in silico pre-
diction (data not shown).
The qNet/torsade metric score metric outperforms 
alternative metrics
Next, we compared the qNet/torsade metric score metric to some 
alternative metrics reported in the literature. To examine their 
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performance over the entire set of CiPA drugs, we combined all 28 
CiPA drugs and used leave- one- out cross- validation to assess the 
prediction accuracy. Of note, these previously suggested metrics, 
like APD907 and APD50 plus diastolic Ca2+ concentration,6 were 
originally developed using different experimental protocols and 
simulation/statistical models, whereas here they are all calculated by 
CiPAORdv1.0 using either the manual or hybrid dataset. The results 
(Table 1) show that the qNet/torsade metric score metric generally 
outperforms the other ones, especially on the measures that evaluate 
across all three categories (pairwise comparison correct rate for rank-
ing and mean classification error for classification). Because the drug 
effects on IKr/hERG were represented by binding dynamic parame-
ters, we also evaluated two additional scenarios where simple hERG 
block potency was used. The first scenario uses only drug IC50s in sta-
tistical equations without the need for physiological models, such as 
the multiple ion channel effects model5 and Bnet,12 whereas the second 
uses IC50s and Hill coefficients for all essential currents (IKr, INaL, 
INa, and ICaL) in CiPAORdv1.0 to calculate metrics. Both scenarios 
gave worse performance than the torsade metric score in Table 1 (see 
Tables 10 and 11 in Validation Report/Supplementary Text S2).
DISCUSSION
In this report, we documented the prediction performance of 
the CiPAORdv1.0 model on the 16 CiPA validation drugs, using 
model, metric, and classification thresholds predefined by the 12 
CiPA training drugs, and performance measures specified prior 
to the validation. Adopting a principle similar to a clinical trial 
design,26 this CiPA model qualification strategy is the most strin-
gent approach so far to evaluate a TdP risk predictor. Even though 
a particular model (CiPAORdv1.0) was used in this study, this 
qualification process could be generally applied to any model to 
evaluate its fitness for regulatory use under the new CiPA paradigm.
Figure 4 The distribution of torsade metric score values for the 16 Comprehensive In Vitro Proarrhythmia Assay (CiPA) validation drugs. For 
each of the validation drugs, 2,000 torsade metric scores are calculated using the Uncertainty Quantification (UQ) method developed earlier17 
to describe the probability distribution of the risk metric. The 95% confidence interval and median point of the 2,000 torsade metric scores for 
each drug are shown as horizontal error bars. Drugs are sorted according to their median torsade metric scores within each category in each 
dataset. Threshold 1 and threshold 2 are predefined by training, as in Figure 2. (a) Results for the manual validation dataset. (b) The hybrid 
validation dataset.
Nifedipine
Nitrendipine
Loratadine
Tamoxifen
Metoprolol
Risperidone
Clarithromycin
Clozapine
Astemizole
Pimozide
Droperidol
Domperidone
Disopyramide
Azimilide
Vandetanib
Ibutilide
0.000 0.025 0.050 0.075
Torsade Metric Score
Nifedipine
Metoprolol
Nitrendipine
Loratadine
Tamoxifen
Risperidone
Clozapine
Clarithromycin
Droperidol
Astemizole
Pimozide
Domperidone
Disopyramide
Azimilide
Vandetanib
Ibutilide
0.000 0.025 0.050 0.075
Torsade Metric Score
High
Intermediate
Low
Threshold 1Threshold 2(a)
(b) Threshold 1Threshold 2
High
Intermediate
Low
ARTICLE
CliniCal PharmaCology & TheraPeuTiCs | VOLUME 0 NUMBER 0 | Month 2018 7
The prespecified performance measures evaluate the accuracy 
of both ranking and classification. It has been suggested that, for 
biomarker- based risk prediction on individual patients, ranking 
along the continuous metric score may be a more realistic repre-
sentation of the risk than specific threshold- based classification.21 
Even though the end point of the CiPA model is a drug’s overall 
TdP risk in the general population rather than on a specific patient, 
the same rationale may apply. Besides, although ranking is solely 
based on a physiological metric (qNet) that is inherent to each 
drug’s electrophysiological properties, classification thresholds are 
established by statistical models and, thus, dependent on other 
drugs in the training set. With the relatively small training set,12 
we expected a better performance using the ranking measures than 
classification. The results are consistent with this hypothesis, and 
some drugs (e.g., risperidone) are indeed incorrectly predicted by 
classification but not ranking. Nevertheless, across two validation 
datasets, the ranking performance measures (five excellent and 
one good) and classification performance measures (five excellent, 
Figure 5 Comparison of the in vitro data for the outliers between the manual and hybrid datasets. The in vitro concentration- dependent block 
data of the three outliers (incorrectly predicted by both ranking and classification) are shown for metoprolol on late sodium current (INaL) 
(a), disopyramide on INaL (b), and domperidone on L-type calcium current (ICaL), and (c) from the manual (left) and hybrid (right) validation 
datasets, respectively. Circles: experimental data points for each cell. Solid line: fitting using median values of concentration of half inhibition 
and Hill coefficient. Gray band: 95% confidence interval of the fitting. Vertical dotted lines: the start and end of the concentration range 
(1–4× maximum free plasma concentration (Cmax)) used for calculating torsade metric score. The mean block% as estimated by the fitted Hill 
equation curves between 1 and 4× Cmax is labeled. Note that for INaL block (a and b), the manual dataset shows much less potency than the 
hybrid dataset, whereas for ICaL (c), the manual dataset shows much higher potency than the hybrid dataset. This explains the emergence of 
outliers unique to each dataset.
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three good, and two minimally acceptable) are all above the pre-
specified acceptable performance levels. Because these predefined 
performance levels are arbitrary, we also compared qNet/torsade 
metric score to alternative metrics, and found a general superior per-
formance (Table 1 and Validation Report). Due to the difference 
in drug block data used and the underlying mathematical models, 
this is a performance comparison within the CiPA framework, not 
a direct examination of the accuracy of the original predictors. This 
partly explains why the measures from some alternative metrics in 
Table 1 are below those originally reported, although the omis-
sion of INaL block data when developing these original metrics5–7 
may also contribute to their suboptimal performance with CiPA 
validation drugs, given that a drug’s significant block on INaL 
may balance off its hERG block effect and reduce its torsadogenic 
potential.24
Some drugs are incorrectly predicted in at least one of the 
validation datasets. One possible reason is these drugs’ complex 
pharmacokinetic or pharmacodynamic effects are not adequately 
captured by the model. For example drug- drug interaction is 
suggested to play a role in torsadogenic potential of antipsy-
chotics, such as clozapine and risperidone,27 and antiemetics like 
domperidone.28 In addition, it has been suggested that risperidone’s 
active metabolite paliperidone plays a more clinically important 
role in disturbing repolarization than the parent drug.29 The actual 
clinical free plasma concentration of disopyamide is subject to not 
only drug- drug interaction30 but also concentration- dependent 
protein binding.31 In addition, some beta- blockers, like metopro-
lol, may have reduced torsadogenic liability through counteracting 
adrenergic- mediated TdP effect32 and protecting against disper-
sion of repolarization.33 Because the model produced mixed results 
for most of these drugs (some correctly predicted by ranking but 
not classification; others correctly predicted in one dataset but not 
the other), it is difficult to estimate to what degree the omission of 
these pharmacological effects in the model negatively impacted the 
prediction. Further studies may be needed to elucidate this.
Another possible reason for incorrect prediction is dataset- specific 
mischaracterization of in vitro data, as suggested by the association 
between the emergence of dataset- specific outliers and the system-
atic in vitro data discrepancy between the two datasets (Figure 5). 
Indeed, the two datasets used quite different experimental condi-
tions on many of the currents (Table 1 of Supplementary Text S1), 
and our own investigation suggests suboptimal quality control pro-
cedures (i.e., lack of control for seal resistance, baseline stability, etc.) 
could have affected some specific IC50 data from both the manual 
and hybrid datasets, which led to the systematic data discrepancy 
between them. A standard operating procedure and unified qual-
ity control criteria are being established under the CiPA initiative, 
which could increase the model prediction accuracy even further.
Although the current model and metric were validated by two 
semi- independent in vitro datasets sharing the same IKr/hERG 
data, additional truly independent data from different laboratories 
will further test the reproducibility of the in vitro data. This may 
enable the development of in silico methods to adjust laboratory- to- 
laboratory variabilities so that all new drugs can be compared to the 
same set of reference drugs and thresholds. In addition, the adop-
tion of CiPA in the early discovery stage would be greatly facilitated 
by adjusting the model and/or experimental protocols so that the 
hERG data can be collected by automated high throughput patch 
clamp systems at ambient temperatures. Nevertheless, the TdP as-
sessment framework described in this report has high accuracy for 
proarrhythmia risk assessment, suggesting it may be fit for CiPA’s 
intended purpose of supporting regulatory decision making.
Table 1 Prediction performance comparison using all CiPA drugs
Performance measure Dataset qnet/torsade metric score aPD90 aPD50 & diastolic Ca
AUC of ROC1 Manual 0.901 (0.883–0.924) 0.842 (0.801–0.877) 0.854 (0.825–0.889)
Hybrid 0.971 (0.936–1) 0.848 (0.807–0.889) 0.854 (0.807–0.906)
AUC of ROC2 Manual 0.988 (0.95–1) 0.975 (0.962–0.988) 0.988 (0.944–1)
Hybrid 0.919 (0.869–0.962) 0.975 (0.956–0.981) 0.969 (0.925–0.981)
Pairwise comparison 
correct rate
Manual 0.929 (0.905–0.943) 0.886 (0.858–0.91) 0.891 (0.829–0.924)
Hybrid 0.943 (0.905–0.976) 0.891 (0.863–0.919) 0.896 (0.858–0.929)
LR+ of threshold 1 Manual 8.05 (4.03–9) 2.53 (1.89–2.84) 4.03 (2.68–4.26)
Hybrid 8.05 (4.03–9.47e+05) 2.68 (2.01–4.03) 3.55 (2.37–4.26)
LR− of threshold 1 Manual 0.0677 (1.13e−06–0.178) 0.189 (0.0789–0.316) 0.135 (0.0677–0.203)
Hybrid 0.0677 (1.12e−06–0.158) 0.158 (0.0789–0.284) 0.203 (0.0789–0.316)
LR+ of threshold 2 Manual 7.5e+05 (8.75–1e+06) 15 (12.5–17.5) 17.5 (15–8.75e+05)
Hybrid 15 (6.25–17.5) 15 (12.5–17.5) 15 (7.5–17.5)
LR− of threshold 2 Manual 0.25 (1e−06–0.263) 0.263 (0.132–0.395) 0.25 (1.05e−06–0.263)
Hybrid 0.263 (0.132–0.395) 0.263 (0.132–0.395) 0.263 (0.132–0.395)
Mean classification 
error
Manual 0.158 (0.155–0.161) 0.305 (0.301–0.309) 0.224 (0.221–0.228)
Hybrid 0.203 (0.201–0.208) 0.285 (0.281–0.289) 0.291 (0.287–0.295)
APD, Action Potential Duration; AUC, area under the curve; Ca, Calcium; CiPA, Comprehensive In Vitro Proarrhythmia Assay; LR, likelihood ratio; ROC, receiver 
under the curve. For each performance measure (row), the values for three metrics (qNet/torsade metric score, APD90, APD50 and diastolic Ca2+) using the two 
datasets (manual and hybrid) are shown. All 28 CiPA drugs are used, with leave- one- out cross- validation to calculate the performance measure. The median as 
well as 95% confidence interval values for each performance measure are listed.
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METHODS
Detailed methods are published previously and/or detailed in 
Supplementary Text S2, with only a few critical aspects of the procedures 
highlighted here.
Experimental procedure
The dynamic hERG protocol16 and manual non- hERG protocols20 were 
published previously. For the hybrid dataset, the block on non- hERG 
currents were measured using CiPA ion channel working group protocols, 
detailed in Supplementary Text S2.
Simulation procedure
The CiPAORdv1.0 model,17 including the dynamic hERG submodel,16 
as well as the qNet metric,15 and the uncertainty quantification 
method to estimate probability distribution and define classification 
thresholds through ordinal logistic regression,17 were all previously 
published. All the software is available at https://github.com/FDA/
CiPA.
Performance measures
All performance measures were predefined in the Validation Strategy 
(Supplementary Text S1). The probability distribution of torsade metric 
scores for each drug was randomly sampled with replacement 10,000 times 
to estimate the median and 95% CI values of performance measures.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Supplementary Text S1. CiPA in silico model validation strategy.
Supplementary Text S2. CiPA in silico model validation report.
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